Confo Therapeutics Selects Discngine’s 3decision® Platform to Leverage the Full Potential of GPCR Structures Towards the Development of Novel Therapeutics
Discngine and Confo Therapeutics are starting strategic collaboration to enhance GPCR drug discovery. Companies aim to further collaborate on the future development of 3decision®.
Discngine partners up with ChemAxon to enhance its 3decision® platform for innovative structure-driven drug discovery
Integrating several of ChemAxon’s cheminformatics and biologics software components into 3decision will expand its capabilities to work on larger biological entities, in addition to the already available features for proteins and small molecules. The registration and visualization of biological entries, like antibodies or peptides, efficient data mining, and advanced analytical capabilities will be accessible.
Discngine and Nanome are partnering up to enhance the structure-based drug design experience
Discngine’s 3decision team is partnering up with Nanome to bring a new dimension to structural analysis. With 3decision in VR, users will be able to entirely exploit the structural knowledge stored in 3decision in a new and advanced way to accelerate drug-design processes.